Melanoscan® Full-Body Digital Imaging Helps Dermatologists Reduce Spread of Deadly Melanomas Through Early Identification

Share Article

Top dermatologists and scientists have collaborated on Melanoscan, an innovative imaging technology to aid in the early discovery of melanoma skin cancer. A new scientific study shows that people at high risk for melanoma and other skin cancers who utilize this Melanoscan technology markedly increase their chances of early detection--critical to preventing the spread of this often fatal disease. Melanomas that are discovered early and successfully treated typically have a 99%+ cure rate.

Melanoscan automation, combined with accurate at-risk population targeting, should allow this new technology to provide a uniquely affordable and high-quality public health solution.

Computer analysis of time lapse whole body digital scanning has allowed a Stamford, CT research team to detect melanomas a significant two years earlier than previously demonstrated. Early discovery dramatically increases the chances of successful treatment. This powerful, revelatory, time-lapse imaging was described in the June 2009 edition of "Dermatology Online Journal".

Prior to this publication, an online melanoma risk screening test was presented at the annual meeting of the Society for Investigative Dermatology in 2006. This 5 minute questionnaire accurately assessed melanoma risk in over 6,000 subjects by correctly predicting who would develop melanoma. The second weapon deployed against melanoma was the skin change detection software technology, Melanoscan®. This melanoma imaging strategy delivered 27 melanomas with an exemplary average cure rate of 99.3%.

No method for earlier detection of melanoma has yet been reported in such a large research series. The entire Melanoscan procedure takes less than 10 minutes and is completely safe, convenient, private, and requires no preparation. To put the patient at ease, automated image capture eliminates any awkwardness associated with photographs taken by a live photo technician. Atypical moles, often considered one of melanoma's most relevant risk factors, are now more easily identified, tracked and monitored. To learn more about melanoma risk factors visit

Dr. Rhett Drugge, the inventor of the Melanoscan and lead researcher of the study states:
"The logistics of saving 7,500 lives every year in the United States through early melanoma detection are clearly daunting. However, the Melanoscan technology can be mobilized and delivered to facilitate early detection, even to the most rural communities. The greatest appeal of this technology lies in its potential to deliver a standardized melanoma screening procedure throughout the United States and beyond. As with most computerized detection strategies, the Melanoscan is a highly reproducible solution, allowing nearly consistent image review and analysis, year over year."

Dr. Drugge continued: "Melanoscan automation, combined with accurate at-risk population targeting, should allow this new technology to provide a uniquely affordable and high-quality public health solution."

Melanoma is the most common cancer in young adults, with the average age of death a mere 47 years. The American Academy of Dermatology reports that in the U.S. one person dies from melanoma every 68 minutes. Screening for early detection of skin cancers is of particular concern today given the recent study published in the journal Lancet Oncology linking the regular use of tanning beds with a significantly increased risk of developing melanoma. The melanoma threat is one of epidemic proportions, with over 62,000 new cases diagnosed in the U.S. alone every year, resulting in over 8,000 deaths. More than half of all global melanoma deaths occur in the United States.

For additional information on this scientific study or for questions relating to the Melanoscan product, contact Steven Scheibel or visit

Melanoscan, Inc., is a medical imaging and technology company, located in Stamford, CT, putting digital imaging technology to work against all forms of skin cancer.


Steven Scheibel, Public Relations
Melanoscan, Inc.
Stamford, CT 06902
(203) 977-8706


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Steven Scheibel

Email >
Visit website